Free Trial

Brokers Set Expectations for ACRV Q1 Earnings

Acrivon Therapeutics logo with Medical background
Remove Ads

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Acrivon Therapeutics in a research note issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.63) for the quarter. HC Wainwright currently has a "Buy" rating and a $19.00 price target on the stock. The consensus estimate for Acrivon Therapeutics' current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics' Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Several other analysts have also recently commented on ACRV. Cantor Fitzgerald restated an "overweight" rating on shares of Acrivon Therapeutics in a research note on Wednesday, March 26th. KeyCorp initiated coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an "overweight" rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $23.17.

Read Our Latest Research Report on ACRV

Acrivon Therapeutics Stock Down 14.5 %

NASDAQ:ACRV traded down $0.30 during midday trading on Friday, reaching $1.74. The stock had a trading volume of 282,732 shares, compared to its average volume of 100,715. The stock has a market cap of $54.02 million, a P/E ratio of -0.64 and a beta of 0.85. The firm has a fifty day simple moving average of $5.27 and a two-hundred day simple moving average of $6.45. Acrivon Therapeutics has a 12-month low of $1.77 and a 12-month high of $11.90.

Remove Ads

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.09.

Institutional Trading of Acrivon Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRV. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at approximately $40,000. Wealthedge Investment Advisors LLC purchased a new stake in Acrivon Therapeutics during the fourth quarter worth $65,000. Corton Capital Inc. acquired a new stake in Acrivon Therapeutics in the fourth quarter valued at $73,000. American Century Companies Inc. increased its position in shares of Acrivon Therapeutics by 14.2% in the fourth quarter. American Century Companies Inc. now owns 17,588 shares of the company's stock valued at $106,000 after buying an additional 2,186 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Acrivon Therapeutics by 20.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company's stock worth $223,000 after buying an additional 6,239 shares during the last quarter. Hedge funds and other institutional investors own 71.62% of the company's stock.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Read More

Earnings History and Estimates for Acrivon Therapeutics (NASDAQ:ACRV)

Should You Invest $1,000 in Acrivon Therapeutics Right Now?

Before you consider Acrivon Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.

While Acrivon Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025
3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads